Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02756286 · ClinicalTrials.gov registry record

Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

A clinical trial of Attention Deficit Hyperactivity Disorder, sponsored by Think Now Incorporated.

Completed
Registry status
258
Enrollment target
3
Study locations

NCT02756286 is a study of Attention Deficit Hyperactivity Disorder that has completed, run by Think Now Incorporated. The registered enrollment target is 258 participants, above the 204-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (26% higher). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02756286, a study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Think Now Incorporated.

COMPLETED
Registry status
258 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.

Interventions

  • OTHER NAT electroencephalography (EEG) test

Study Locations (3)

California

  • University of California Berkeley - Berkeley
  • UCLA Semel Institute - Los Angeles

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 258 participants
Start Date 2017-01-01
Est. Completion 2018-07-05

Sponsor

Think Now Incorporated

4 total trials

What the Registry Record Tells You About NCT02756286

The ClinicalTrials.gov registry entry for NCT02756286 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 204-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (26% higher). The listed sponsor is Think Now Incorporated, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which NAT electroencephalography (EEG) test is the first listed.

NCT02756286 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Oregon.

Frequently Asked Questions

What is clinical trial NCT02756286 about?

NCT02756286 is a clinical study titled "Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD". The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.

What is the current status of trial NCT02756286?

This trial is currently completed. The enrollment target is 258 participants. The study started on 2017-01-01. Estimated completion is 2018-07-05.

What conditions does trial NCT02756286 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT02756286?

The interventions under investigation include: NAT electroencephalography (EEG) test (OTHER).

Who is sponsoring clinical trial NCT02756286?

This trial is sponsored by Think Now Incorporated, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02756286 being conducted?

This trial has 3 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.